International Journal of Drug Delivery Technology
Volume 14, Issue 3

Oral Insulin: Challenges and Potential Solutions with a Case Study of Pharmaceutical Company Ventures

Anirudh R URS, Priyanka R Bhargav, Shreya Shanbhog, Manish Danda, Narendra Kumar S*

Department of Biotechnology, RV College of Engineering, Bengaluru, Karnataka, India.

Received: 05th May, 2024; Revised: 08th June, 2024; Accepted: 13th June, 2024; Available Online: 25th September, 2024 

ABSTRACT

Oral insulin, in pill form, presents a non-injectable alternative. It is a transformative approach to diabetes management, potentially enhancing patient compliance. This paper examines challenges and potential solutions in oral insulin development, which are further bolstered by a case study on pharmaceutical ventures, namely, oramed, diasome, diabetology, biocon and emisphere.

Keywords: Oral insulin, Pharmaceutical, Diabetes, Medicine, Clinical Trials. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.3.70

How to cite this article: Anirudh RURS, Bhargav PR, Shanbhog S, Danda M, Kumar NS. Oral Insulin: Challenges and Potential Solutions with a Case Study of Pharmaceutical Company Ventures. International Journal of Drug Delivery Technology. 2024;14(3):1745-1748.

REFERENCES

  1. (n.d.). Diabetics number top countries 2021. Retrieved fromhttps://www.statista.com/statistics/281082/countries- with-highest-number-of-diabetics/
  2. Research. (n.d.). Insulin Market Size, Share and Growth Analysis Report 2031. Retrieved from https://straitsresearch.com/report/insulin-market
  3. FutureWiseResearch: Global Market Research Reports, USA,                     (n.d.).        Retrieved     from https://www.futurewiseresearch.com/404
  4. Martin, A. L. A., & Martin, M. M. (1978). Continuous infusion of insulin vs repeated S.C. injections in the treatment of diabetic ketoacidosis in children. Acta Lat.,                15(1),                81–87. https://doi.org/10.1007/BF02581010
  5. Jeitler, , et al. (2008). Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta- analysis. Diabetologia,              51(6),     941–951. https://doi.org/10.1007/s00125-008-0974-3
  6. Iyer, , Khedkar, A., & Verma, M. (2010). Oral insulin – A review of current status. Diabetes Obes. Metab., 12(3), 179–185. https://doi.org/10.1111/j.1463- 1326.2009.01150.x
  7. Yaturu, S. (2013). Insulin therapies: Current and future trends at dawn. World J. Diabetes, 4(1), 1–7. https://doi.org/10.4239/wjd.v4.i1.1
  8. Baruah, M. P. (2011). Insulin pens: The modern delivery devices. J. Assoc. Physicians India, 59(Suppl), 38–40.
  9. Arbit, E., & Kidron, M. (2009). Oral Insulin: The Rationale for This Approach and Current Developments.
  10. Diabetes Sci. Technol., 3(3), 562–567. https://doi.org/10.1177/193229680900300322
  11. Recent advancements on novel approaches of insulin delivery - ScienceDirect. (n.d.). Retrieved from https://sciencedirect.com/science/article/pii/S25900 93523000486
  12. Oral Insulin Delivery Platforms: Strategies To Address the Biological Barriers - Xiao - 2020 - Angewandte Chemie International Edition - Wiley Online Library. (n.d.). Retrieved from
  13. https://onlinelibrary.wiley.com/doi/10.1002/anie.2020088 79
  14. Carino, G. P., & Mathiowitz, E. (1999). Oral insulin delivery. Adv. Drug Deliv. Rev., 35(2), 249–257. https://doi.org/10.1016/S0169-409X(98)00075-1
  15. Weinstock, R. S., et al. (2022). Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes. Metab., 24(9), 1762–1769. https://doi.org/10.1111/dom.14761
  16. Mucus Penetrating and Cell‐Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery - Fan - 2022 - Advanced Materials - Wiley Online Library. (n.d.). Retrieved from https://onlinelibrary.wiley.com/doi/10.1002/adma.202109 189
  17. Heinemann, L., & Jacques, Y. (2009). Oral Insulin and Buccal Insulin: A Critical Reappraisal. J. Diabetes Sci. , 3(3), 568–584.https://doi.org/10.1177/193229680900300323